The Defense Ministry-run Israel Institute for Biological Research (IIBR) announced Monday that it had inked a memorandum of understanding with the Nasdaq-traded NRx Pharmaceuticals to complete the clinical trials of its homegrown COVID-19 vaccine.
NRx Pharmaceuticals will send the vaccine, known as Brilife, to third-stage clinical trials, which will be conducted on tens of thousands of volunteers in Georgia, Ukraine and Israel, the Defense Ministry said in a statement. The pharmaceutical company will then oversee its commercialization, The Times of Israel reports.
Defense Minister Benny Gantz hailed the agreement, calling it “excellent news.”
